
In Stock
10mg
GHRH Receptor Binding & Sustained GH Release
CJC-1295 with DAC is a focus for researchers studying the somatotropic axis. It engages GHRH receptors in the anterior pituitary to stimulate growth hormone synthesis and release. The Drug Affinity Complex enables covalent binding to circulating albumin, extending functional activity to several days. Studies use this property to model continuous, non-pulsatile somatotropic stimulation and how it differs from the short bursts produced by native GHRH.
Serum Albumin Conjugation & Half-Life
In peptide research, CJC-1295 DAC is investigated for the mechanics of its albumin-binding modification. Researchers study how the DAC moiety protects the peptide from enzymatic degradation and renal clearance, examining the pharmacokinetic basis for its extended duration of action within preclinical models.
Metabolic & Somatotropic Axis Effects
Recent studies have utilized CJC-1295 DAC to investigate downstream effects on the GH/IGF-1 axis. By examining how prolonged somatotropic signaling influences lipid metabolism, protein synthesis, and substrate utilization, researchers explore the distinction between chronic and acute hormonal exposure in metabolic models.
Supplied as a purified, lyophilized powder, it is intended strictly for laboratory research; it is not for human or veterinary administration.
For research use only.
testimonials
peptides
Our most popular peptides, in high-demand this year

verified coa's
The most powerful weight loss peptide studied, with clinical trials showing up to 24% body weight reduction in 48 weeks.
Trusted by 150+ Customers
